Search CRL
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NYSE · CIK 1100682
Last close290.19
Daily change+3.36 (1.17%)
10 Years gain+246.79%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CRL · STANDARD
SIC 8731 · Services-Commercial Physical & Biological Research · Fiscal year end 1227
Fundamental
34.7Momentum
50.4Acceleration
50.4Confidence
79.0Annual Revenue18
Quarterly Revenue72
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth2.3 / 25
Quality7.7 / 25
Capital Efficiency10.7 / 20
Balance Sheet14.1 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 0.0842 percentage points.
Share count reductionDiluted share count declined 5.569%.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Key Metrics
Revenue Growth TTM0.13%OK
Revenue CAGR 3Y0.33%OK
Gross Marginn/aMISSING
Operating Margin11.73%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC13.32%OK
Incremental Operating Margin 3Y-59.92%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-5.57%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 27, 2025 | $4.02B | n/a | $25.16M | $737.65M | $518.49M | n/a | 0.63% | 12.91% | 0.64% | 49.56M |
| 2025 FY Dec 28, 2024 | $4.05B | n/a | $227.35M | $734.58M | $501.61M | n/a | 5.61% | 12.39% | 4.48% | 51.63M |
| 2025 FY Dec 30, 2023 | $4.13B | n/a | $617.26M | $683.90M | $365.37M | n/a | 14.95% | 8.85% | 16.82% | 51.45M |
| 2024 FY Dec 31, 2022 | $3.98B | n/a | $650.98M | $619.64M | $294.91M | n/a | 16.37% | 7.42% | 20.44% | 51.3M |
| 2023 FY Dec 25, 2021 | $3.54B | n/a | $589.86M | $760.80M | $532.03M | n/a | 16.66% | 15.03% | 23.17% | 51.43M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $4.04B | sum latest 4 fiscal quarters Revenue | OK | 0001100682-26-000118, 0001100682-25-000043 |
| Revenue Growth TTM | 0.13% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001100682-26-000118, 0001100682-25-000043 |
| Revenue CAGR 3Y | 0.33% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001100682-26-000022 |
| Revenue CAGR 5Y | 6.55% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001100682-26-000022 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | derived |
| Operating Income Growth | 0.85% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001100682-26-000118, 0001100682-25-000043 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Margin | 11.73% | Operating Income / Revenue | OK | 0001100682-26-000118, 0001100682-25-000043 |
| ROIC | 13.32% | NOPAT / Average Invested Capital | OK | 0001100682-26-000118, 0001100682-25-000043 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001100682-26-000118 |
| Current Ratio | 1.35x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 35.17x | (Cash + Short-term Investments) / Total Debt | OK | 0001100682-26-000118 |
| Revenue per Diluted Share | $84.07 | Revenue / Diluted Shares | OK | 0001100682-26-000118, 0001100682-25-000043 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |